Bordonaro, R. Calvo, A. Auriemma, A. Hollebecque, A. Rubovszky, G. Saunders, M.P. Pápai, Z. Prager, G. Stein, A. André, T.
...
Published in
ESMO Open
• This study evaluated the safety and efficacy of FTD/TPI plus oxaliplatin and either bevacizumab or nivolumab in mCRC patients. • FTD/TPI plus oxaliplatin in combination with bevacizumab or nivolumab had an acceptable and manageable safety profile. • Antitumour activity was observed following treatment with FTD/TPI plus oxaliplatin and bevacizumab...
Kossai, M. Radosevic-Robin, N. Penault-Llorca, F.
Published in
ESMO Open
• At present, immune checkpoint inhibitors (ICIs) are the only approved immunotherapy drugs in BC. • Tumour PD-L1 and microsatellite status are current companion biomarkers for ICIs in BC; however, these need improvement. • Evaluation of tumour immune contexture and the dynamics of circulating immune cell counts are promising novel approaches. • De...
Garutti, M. Lambertini, M. Puglisi, F.
Published in
ESMO Open
• This review collected the available evidence on the role of immunotherapy on fertility, hypogonadism, and sexuality. • Immune checkpoint inhibitors could impair fertility. • Immunotherapy can cause primary hypogonadism and secondary hypogonadism. • Immune checkpoint inhibitors have to be avoided during or shortly before pregnancy. • Immunotherapy...
Grinshpun, A. Rottenberg, Y. Ben-Dov, I.Z. Djian, E. Wolf, D.G. Kadouri, L.
Published in
ESMO Open
Background It was shown that immunocompromised patients have significantly reduced immunologic responses to COVID-19 vaccines. The immunogenicity of COVID-19 vaccine/infection in patients with solid tumors is reduced. We evaluated the immunologic response to COVID-19 and/or the BNT162b2 mRNA COVID-19 vaccine among cancer patients on active treatmen...
Gaspar, N. Campbell-Hewson, Q. Gallego Melcon, S. Locatelli, F. Venkatramani, R. Hecker-Nolting, S. Gambart, M. Bautista, F. Thebaud, E. Aerts, I.
...
Published in
ESMO Open
• The recommended phase II dose of lenvatinib in children with relapsed/refractory solid malignant tumors is 14 mg/m2. • This dose is equivalent to the recommended dose of 24 mg/day for single-agent lenvatinib in adults with DTC. • Single-agent lenvatinib showed activity of interest in children and young adults with osteosarcoma. • Based on this in...
Planchard, D. Feng, P.-H. Karaseva, N. Kim, S.-W. Kim, T.M. Lee, C.K. Poltoratskiy, A. Yanagitani, N. Marshall, R. Huang, X.
...
Published in
ESMO Open
• FLAURA2 aims to assess efficacy and safety of first-line osimertinib with platinum–pemetrexed in EGFRm advanced NSCLC. • In the FLAURA2 safety run-in period, 30 patients received osimertinib and pemetrexed with carboplatin or cisplatin. • Most common AEs were constipation and nausea; no AE patterns leading to dose modifications/discontinuations w...
Hou, N. Wu, J. Xiao, J. Wang, Z. Song, Z. Ke, Z. Wang, R. Wei, M. Xu, M. Wei, J.
...
Published in
ESMO Open
• Establishing the first risk stratification nomogram for BC treated with NAC and validate its performance in BC cohorts. • Incorporating residual cancer burden index into predictive nomogram for the first time. • Predictive model can be utilized to predict DFS for all early-stage BC treated with NAC. • Performing a continuous rather than categoriz...
Kulkarni, A.A. Rubin, N. Tholkes, A. Shah, S. Ryan, C.J. Lutsey, P.L. Prizment, A. Rao, A.
Published in
ESMO Open
• Abiraterone and enzalutamide have comparable efficacy but substantial differences in CV toxicity. • We identified metastatic PC patients treated with ADT and abiraterone or enzalutamide from insurance claims-based database. • Abiraterone use was associated with a 31% increased risk for MI or stroke when compared to enzalutamide. • Enzalutamide ma...
Del Re, M. Omarini, C. Diodati, L. Palleschi, M. Meattini, I. Crucitta, S. Lorenzini, G. Isca, C. Fontana, A. Livi, L.
...
Published in
ESMO Open
• PPIs are widely used in cancer patients to manage chemotherapy-related gastrointestinal adverse events. • Palbociclib is a weak base with a pH-dependent solubility. • Breast cancer patients treated with palbociclib and PPIs have significantly shorter PFS. • Drug-drug interactions should be clearly evaluated in patients taking PPIs.
Younger, E. Jones, R.L. den Hollander, D. Soomers, V.L.M.N. Desar, I.M.E. Benson, C. Young, R.J. Oosten, A.W. de Haan, J.J. Miah, A.
...
Published in
ESMO Open
• All younger patients (
